You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
Under the LCD, oncology biomarkers must have proven clinical validity and there must be acceptance of specific testing into patient management.
The general LCD is covered for patients with a personal history of melanoma undergoing workups or being evaluated for treatment without metastatic disease.
The firm said that it has secured coverage for about 100 million lives for its targeted NGS liquid biopsy test in the US between Medicare and private payors.
CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.
The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.
The draft LCD would cover the Signatera minimal residual disease test for several solid tumor types and indications, including immunotherapy response monitoring.
The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.
The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.
In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.